Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

Related Articles by Review for PubMed (Select 23137412)

1.

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.

Lajara R.

Expert Opin Pharmacother. 2012 Dec;13(18):2663-71. doi: 10.1517/14656566.2012.741591. Epub 2012 Nov 9. Review.

PMID:
23137412
2.

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.

von Websky K, Reichetzeder C, Hocher B.

Vasc Health Risk Manag. 2013;9:681-94. doi: 10.2147/VHRM.S40035. Epub 2013 Nov 1. Review.

3.

Review of linagliptin for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Setter SM.

Clin Ther. 2012 May;34(5):993-1005. doi: 10.1016/j.clinthera.2012.02.029. Epub 2012 Mar 21. Review.

PMID:
22440191
4.

Linagliptin: a review of its use in the management of type 2 diabetes mellitus.

Deeks ED.

Drugs. 2012 Sep 10;72(13):1793-824. doi: 10.2165/11209570-000000000-00000. Review. Erratum in: Drugs. 2013 Jan;73(1):99.

PMID:
22913735
5.

Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Toth PP.

Postgrad Med. 2011 Jul;123(4):46-53. doi: 10.3810/pgm.2011.07.2303. Review.

PMID:
21680988
6.

Linagliptin: in type 2 diabetes mellitus.

Scott LJ.

Drugs. 2011 Mar 26;71(5):611-24. doi: 10.2165/11207400-000000000-00000. Review.

PMID:
21443284
7.

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

Forst T, Pfützner A.

Expert Opin Pharmacother. 2012 Jan;13(1):101-10. doi: 10.1517/14656566.2012.642863. Review.

PMID:
22149370
8.

Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.

Grunberger G.

Postgrad Med. 2013 May;125(3):79-90. doi: 10.3810/pgm.2013.05.2663. Review.

PMID:
23748509
9.

Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.

Aletti R, Cheng-Lai A.

Cardiol Rev. 2012 Jan-Feb;20(1):45-51. doi: 10.1097/CRD.0b013e31823a3afc. Review.

PMID:
22143285
10.

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.

Barnett AH.

Adv Ther. 2011 Jun;28(6):447-59. doi: 10.1007/s12325-011-0028-y. Epub 2011 May 17. Review.

PMID:
21603986
11.

[Oral Linagliptin (Trajenta)].

Duh D, Tanret I.

J Pharm Belg. 2013 Mar;(1):41-3. Review. French. No abstract available.

PMID:
23638612
12.

Linagliptin: from bench to bedside.

Doupis J.

Drug Des Devel Ther. 2014 May 5;8:431-46. doi: 10.2147/DDDT.S59523. eCollection 2014. Review.

13.

[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].

Scheen AJ, Van Gaal LF.

Rev Med Liege. 2013 Sep;68(9):479-85. Review. French.

PMID:
24180204
14.

Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Tiwari A.

Curr Opin Investig Drugs. 2009 Oct;10(10):1091-104. Review.

PMID:
19777398
15.

Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):363-77. doi: 10.1517/17425255.2013.767892. Epub 2013 Feb 4. Review.

PMID:
23373842
16.

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1561-76. doi: 10.1517/17425255.2011.628986. Epub 2011 Oct 25. Review.

PMID:
22022857
17.

Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.

Ghatak SB, Patel DS, Shanker N, Srivastava A, Deshpande SS, Panchal SJ.

Curr Diabetes Rev. 2011 Sep;7(5):325-35. Review.

PMID:
21916836
18.

Efficacy and safety of Jentadueto® (linagliptin plus metformin).

Scheen AJ.

Expert Opin Drug Saf. 2013 Mar;12(2):275-89. doi: 10.1517/14740338.2013.771631. Review.

PMID:
23421949
19.

Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.

Koliaki C, Doupis J.

Adv Ther. 2012 Dec;29(12):993-1004. doi: 10.1007/s12325-012-0067-z. Epub 2012 Nov 23. Review.

PMID:
23184570
20.

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.

Deacon CF, Holst JJ.

Expert Opin Investig Drugs. 2010 Jan;19(1):133-40. doi: 10.1517/13543780903463862. Review.

PMID:
19947894
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk